June 21, 2006 – Gaboxadol, a novel sedative from Merck and Lundbeck, produced positive Phase II data; Cortex said CX717was not effective in promoting alertness for night workers; Arena presented positive results from a Phase I test of APD125; Sepracor touted results from post-approval studies of Lunestra; Genentech extended its indication for Avastin; Celera Genomics sold its small molecule drug program to Schering; Cell Therapeutics placed up to $55 million in stock with Societe Generale; Bioenvision said Evoltra was effective against acute myeloid leukemia in a Phase II trial; Salix Pharma reported the FDA set August 2, 2006 as the action date for MoviPrep; and Auxilium said its injectable enzyme was effective against Dupuytren’s Disease. The Centient Biotech 200™ climbed 25 points to 3568.90, a rise of .69%. More details...
